SCHEMBL2513699 — predicted protein targets

Predicted protein targets (top 19)

	gene	UniProt	supporting neighbours	confidence
▸	CYP11B1	P15538	8/20	0.49

▸	CYP11B2	P19099	8/20	0.49

▸	TNF	P01375	2/20	0.49

▸	LMNA	P02545	6/20	0.48

▸	SMN1; SMN2	Q16637	6/20	0.48

▸	HTT	P42858	5/20	0.48

▸	L3MBTL1	Q9Y468	1/20	0.48

▸	TSHR	P16473	2/20	0.46

▸	MAPK1	P28482	2/20	0.46

▸	MEN1	O00255	1/20	0.46

▸	KMT2A	Q03164	1/20	0.46

▸	ALOX15	P16050	1/20	0.46

▸	NPSR1	Q6W5P4	1/20	0.45

▸	ALDH1A1	P00352	1/20	0.45

▸	AGER	Q15109	1/20	0.43

▸	TDP1	Q9NUW8	1/20	0.43

▸	PKM	P14618	1/20	0.43

▸	MAPT	P10636	1/20	0.43

▸	STAT3	P40763	1/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL7983724	0.87	SMN1; SMN2 (0.55)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7983841	0.82	SMN1; SMN2 (0.50)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7983835	0.82	SMN1; SMN2 (0.47)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7994647	0.81	SMN1; SMN2 (0.49)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL8001463	0.81	SMN1; SMN2 (0.49)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7983909	0.81	SMN1; SMN2 (0.49)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7995844	0.80	SMN1; SMN2 (0.48)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7997809	0.78	CYP11B1 (0.57)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7984266	0.77	SMN1; SMN2 (0.43)	CYP11B1CYP11B2TNFLMNASMN1; SMN2
SCHEMBL7983461	0.75	HPGD (0.38)	LMNAHTTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20100256181-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	MERCK SHARP & DOHME LLC	2010-10-07	—	—	US	claimed
EP-2222661-A2	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	Merck Sharp & Dohme Corp. (US)	2010-09-01	—	—	EP	claimed
WO-2009067166-A2	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	MERCK & CO., INC. (US)	2009-05-28	—	—	WO	claimed
WO-2001034578-A1	COMPOUNDS WITH ANTI-HELICOBACTER PYLORI ACTIVITY	ASTRAZENECA AB (SE)	2001-05-17	—	—	WO	claimed
EP-3656384-B1	COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV	MERCK SHARP & DOHME (US)	2022-02-23	—	—	EP	disclosed
EP-3785714-A1	PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS	MERCK SHARP & DOHME CORP. (US)	2021-03-03	—	—	EP	disclosed
EP-3125894-B1	PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS	MERCK SHARP & DOHME (US)	2020-09-09	—	—	EP	disclosed
EP-3656384-A1	COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV	MERCK SHARP & DOHME CORP. (US)	2020-05-27	—	—	EP	disclosed
EP-3295942-B1	COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV	MERCK SHARP & DOHME (US)	2019-11-20	—	—	EP	disclosed
US-10189831-B2	Non-nucleoside reverse transcriptase inhibitors	MERCK SHARP & DOHME CORP. (US)	2019-01-29	—	—	US	disclosed
US-10004740-B2	Prodrugs of HIV reverse transcriptase inhibitors	MERCK SHARP & DOHME CORP. (US)	2018-06-26	—	—	US	disclosed
EP-3295942-A1	COMBINATIONS COMPRISING 5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE FOR THE PROPHYLAXIS OR TREATMENT OF INFECTION BY HIV	MERCK SHARP & DOHME CORP. (US)	2018-03-21	—	—	EP	disclosed
US-8404856-B2	Non-nucleoside reverse transcriptase inhibitors	MERCK SHARP & DOHME CORP. (US)	2013-03-26	—	—	US	disclosed
EP-2552902-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	Merck Canada Inc. (CA)	2013-02-06	—	—	EP	disclosed
WO-2011120133-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	MERCK FROSST CANADA LTD. (CA)	2011-10-06	—	—	WO	disclosed
US-20110245296-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	MERCK CANADA INC. (CA)	2011-10-06	—	—	US	disclosed
US-20100256181-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	MERCK SHARP & DOHME LLC	2010-10-07	—	—	US	disclosed
EP-2222661-A2	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	Merck Sharp & Dohme Corp. (US)	2010-09-01	—	—	EP	disclosed
WO-2009067166-A2	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	MERCK & CO., INC. (US)	2009-05-28	—	—	WO	disclosed
WO-2001034578-A1	COMPOUNDS WITH ANTI-HELICOBACTER PYLORI ACTIVITY	ASTRAZENECA AB (SE)	2001-05-17	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-10004740-B2	Prodrugs of HIV reverse transcriptase inhibitors	TYMP, RNGTT, REV1	CYP11B1 791/4885CYP11B2 1283/4885TNF 1922/4885
US-10189831-B2	Non-nucleoside reverse transcriptase inhibitors	POLRMT, POLR2E, RTF1	CYP11B1 2617/4885CYP11B2 2973/4885TNF 1925/4885
US-20100256181-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	POLB, POLR2A, RRM2B	CYP11B1 1814/4885CYP11B2 2547/4885TNF 2634/4885
US-20110245296-A1	NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	POLRMT, REV1, POLR2E	CYP11B1 1420/4885CYP11B2 1995/4885TNF 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.